Nitazoxanide Dosage

Medically reviewed by Drugs.com. Last updated on Feb 5, 2024.

Usual Adult Dose for Cryptosporidiosis

500 mg orally every 12 hours for 3 days

Use: For the treatment of diarrhea due to Giardia lamblia or Cryptosporidium parvum

Usual Adult Dose for Giardiasis

500 mg orally every 12 hours for 3 days

Use: For the treatment of diarrhea due to Giardia lamblia or Cryptosporidium parvum

Usual Pediatric Dose for Cryptosporidiosis

1 to 3 years: 100 mg orally every 12 hours
4 to 11 years: 200 mg orally every 12 hours
12 years or older: 500 mg orally every 12 hours

Duration of Therapy: 3 days

Use: For the treatment of diarrhea due to G lamblia or C parvum

Usual Pediatric Dose for Giardiasis

1 to 3 years: 100 mg orally every 12 hours
4 to 11 years: 200 mg orally every 12 hours
12 years or older: 500 mg orally every 12 hours

Duration of Therapy: 3 days

Use: For the treatment of diarrhea due to G lamblia or C parvum

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
Prior hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer with food.
• Do not use the tablets for pediatric patients 11 years or younger.
• Shake the oral suspension well before each use; discard unused oral suspension after 7 days.

Storage requirements:

• Oral suspension:
• Unsuspended powder: Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
• Reconstituted suspension: May store for 7 days at room temperature; keep bottle tightly closed.
• Tablets: Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).

Reconstitution/preparation techniques:

• Oral suspension: The manufacturer product information should be consulted.

General:

• Limitations of Use: Efficacy for the treatment of diarrhea due to C parvum has not been established in HIV-infected or immunodeficient patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer